Aktie A2PCAX PHARMACIELO LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen PharmaCielo Ltd.

Aktien

A2PCAX

CA71716K1012

PCLO

Markt geschlossen - Toronto S.E.
Andere Börsenplätze
 20:42:23 19.04.2024 		% 5 Tage % 1. Jan.
0,18 CAD +2,86 % Intraday Chart für PharmaCielo Ltd. -18,18 % 0,00 %
04.01. Benuvia und PharmaCielo geben strategische Partnerschaft zur Herstellung von CBD-Isolat in pharmazeutischer Qualität nach cGMP und verwandten Produkten bekannt CI
2023 PharmaCielo Ltd. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
PharmaCielo Signs Binding Letter of Intent to Acquire Operations in Thailand; Announces $2 Million Non-Brokered Private Placement with Participation from PharmaCielo Insiders and Siam Ventures Investors
PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding
PharmaCielo to Supply Ease Labs with Commercial Shipments of API to Fulfill Contract with State Government of Sao Paulo, Brazil
Colombian Government Continues its Support of Domestic Cannabis Industry - Resolution Extending THC Inventory Allowance Provides Immediate Benefit to PharmaCielo
Benuvia and PharmaCielo Announce Strategic Partnership to Manufacture cGMP Pharmaceutical-Grade CBD Isolate and Related Products
Benuvia and PharmaCielo Announce Strategic Partnership to Manufacture cGMP Pharmaceutical-Grade CBD Isolate and Related Products
PharmaCielo Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
PharmaCielo Announces Q3 2023 Financial Results
PharmaCielo Raises $3.3 Million Under Non-Brokered Private Placement
PharmaCielo Raises $3.3 Million Under Previously Announced Non-Brokered Private Placement
PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding
PharmaCielo Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Pharmacielo Ltd. Appoints Marc Lustig as CEO
Pharmacielo Ltd. Announces Board Changes
PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding
PharmaCielo Ltd. announced that it has received CAD 12.825 million in funding
PharmaCielo Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
PharmaCielo Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
PharmaCielo Ltd. Auditor Raises 'Going Concern' Doubt
PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company Represents Third Customer in the Country
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PCAX Aktie
  4. Nachrichten PharmaCielo Ltd.
  5. Andere Sprachen